B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
Cumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research in exploring the utility of targeting B cells to...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129906/full |
| _version_ | 1811157642055254016 |
|---|---|
| author | Moritz J. Furman Sven G. Meuth Philipp Albrecht Philipp Albrecht Michael Dietrich Heike Blum Jan Mares Ron Milo Hans-Peter Hartung Hans-Peter Hartung Hans-Peter Hartung |
| author_facet | Moritz J. Furman Sven G. Meuth Philipp Albrecht Philipp Albrecht Michael Dietrich Heike Blum Jan Mares Ron Milo Hans-Peter Hartung Hans-Peter Hartung Hans-Peter Hartung |
| author_sort | Moritz J. Furman |
| collection | DOAJ |
| description | Cumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research in exploring the utility of targeting B cells to contain disease activity in these disorders. In this review, we first recapitulate the development of B cells from their origin in the bone marrow to their migration to the periphery, including the expression of therapy-relevant surface immunoglobulin isotypes. Not only the ability of B cells to produce cytokines and immunoglobulins seems to be essential in driving neuroinflammation, but also their regulatory functions strongly impact pathobiology. We then critically assess studies of B cell depleting therapies, including CD20 and CD19 targeting monoclonal antibodies, as well as the new class of B cell modulating substances, Bruton´s tyrosinekinase (BTK) inhibitors, in MS, NMOSD and MOGAD. |
| first_indexed | 2024-04-10T05:09:36Z |
| format | Article |
| id | doaj.art-9e0e0ed8ac634010b2533b9df63f19b4 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T05:09:36Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-9e0e0ed8ac634010b2533b9df63f19b42023-03-09T10:48:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11299061129906B cell targeted therapies in inflammatory autoimmune disease of the central nervous systemMoritz J. Furman0Sven G. Meuth1Philipp Albrecht2Philipp Albrecht3Michael Dietrich4Heike Blum5Jan Mares6Ron Milo7Hans-Peter Hartung8Hans-Peter Hartung9Hans-Peter Hartung10Department of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, GermanyDepartment of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, GermanyDepartment of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, GermanyDepartment of Neurology, Maria Hilf Clinic, Moenchengladbach, GermanyDepartment of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, GermanyDepartment of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, GermanyDepartment of Neurology, Palacky University in Olomouc, Olomouc, CzechiaDepartment of Neurology, Barzilai Medical Center, Ashkelon, IsraelDepartment of Neurology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, GermanyDepartment of Neurology, Palacky University in Olomouc, Olomouc, CzechiaBrain and Mind Center, Medical Faculty, The University of Sydney, Sydney, NSW, AustraliaCumulative evidence along several lines indicates that B cells play an important role in the pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders (NMOSD) and related CNS diseases. This has prompted extensive research in exploring the utility of targeting B cells to contain disease activity in these disorders. In this review, we first recapitulate the development of B cells from their origin in the bone marrow to their migration to the periphery, including the expression of therapy-relevant surface immunoglobulin isotypes. Not only the ability of B cells to produce cytokines and immunoglobulins seems to be essential in driving neuroinflammation, but also their regulatory functions strongly impact pathobiology. We then critically assess studies of B cell depleting therapies, including CD20 and CD19 targeting monoclonal antibodies, as well as the new class of B cell modulating substances, Bruton´s tyrosinekinase (BTK) inhibitors, in MS, NMOSD and MOGAD.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129906/fullB cell depletionmultiple sclerosis (MS)neuromyelitisoptica spectrum disorders (NMOSD)myelin oligodendrocyte glycoprotein associated autoimmune disease (MOGAD)autoimmune disease of the central nervous system |
| spellingShingle | Moritz J. Furman Sven G. Meuth Philipp Albrecht Philipp Albrecht Michael Dietrich Heike Blum Jan Mares Ron Milo Hans-Peter Hartung Hans-Peter Hartung Hans-Peter Hartung B cell targeted therapies in inflammatory autoimmune disease of the central nervous system Frontiers in Immunology B cell depletion multiple sclerosis (MS) neuromyelitisoptica spectrum disorders (NMOSD) myelin oligodendrocyte glycoprotein associated autoimmune disease (MOGAD) autoimmune disease of the central nervous system |
| title | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system |
| title_full | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system |
| title_fullStr | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system |
| title_full_unstemmed | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system |
| title_short | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system |
| title_sort | b cell targeted therapies in inflammatory autoimmune disease of the central nervous system |
| topic | B cell depletion multiple sclerosis (MS) neuromyelitisoptica spectrum disorders (NMOSD) myelin oligodendrocyte glycoprotein associated autoimmune disease (MOGAD) autoimmune disease of the central nervous system |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1129906/full |
| work_keys_str_mv | AT moritzjfurman bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT svengmeuth bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT philippalbrecht bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT philippalbrecht bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT michaeldietrich bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT heikeblum bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT janmares bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT ronmilo bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT hanspeterhartung bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT hanspeterhartung bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem AT hanspeterhartung bcelltargetedtherapiesininflammatoryautoimmunediseaseofthecentralnervoussystem |